We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · July 27, 2021

IRAEs as Biomarkers in Metastatic RCC Treated With ICIs

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Immune-Related Adverse Events as Clinical Biomarkers in Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
Oncologist 2021 Jun 22;[EPub Ahead of Print], DJ Martini, S Goyal, Y Liu, ST Evans, TA Olsen, K Case, BL Magod, JT Brown, L Yantorni, GA Russler, S Caulfield, JM Goldman, B Nazha, WB Harris, HT Kissick, VA Master, O Kucuk, BC Carthon, MA Bilen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading